Table 2.
Systemic therapies based on subtype in patients aged 50–69 years (ESG) and patients ≥70 years (NESG), n = 3463 patients
| Luminal A | Luminal B | HER2-like | Basal-like | Total | ||||||
|---|---|---|---|---|---|---|---|---|---|---|
| ESG(%) | NESG (%) | ESG (%) | NESG (%) | ESG (%) | NESG (%) | ESG(%) | NESG (%) | ESG (%) | NESG (%) | |
| ET (n = 1719/49.6%) | 700/63.0 | 455/69.0 | 205/40.7 | 212/63.7 | 68/18.1 | 76/36.5 | 1/0.6 | 2/2.2 | 974/44.9 | 745/57.7 |
| CHT + ET (n = 703/20.3%) | 296/26.6 | 42/6.4 | 240/47.6 | 39/11.7 | 70/18.6 | 7/3.4 | 8/4.4 | 1/1.1 | 614/28.3 | 89/6.9 |
| CHT + ET + Trastuzumab (n = 128/3.7%) | – | – | – | – | 104/27.7 | 24/11.5 | – | – | 104/4.8 | 24/1.9 |
| CHT + Trastuzumab (n = 75/2.2%) | – | – | – | – | 60/16.0 | 15/7.2 | – | – | 60/2.8 | 15/1.2 |
| ET + Trastuzumab (n = 13/0.4%) | – | – | – | – | 7/1.9 | 6/2.9 | – | – | 7/0.3 | 6/0.5 |
| CHT (n = 279/8.1%) | 25/2.3 | 7/1.1 | 26/5.2 | 1/0.3 | 37/9.8 | 10/4.8 | 140/77.8 | 33/35.9 | 228/10.5 | 51/3.9 |
| None (n = 546/15.8%) | 90/8.1 | 155/23.5 | 33/6.5% | 81/24.3 | 30/7.9 | 70/33.7 | 31/17.2 | 56/60.9 | 184/8.5 | 362/27.9 |
| Total | 1111/51.2 | 659/51.0 | 504/23.2 | 333/25.8 | 376/17.3 | 208/16.1 | 180/8.3 | 92/7.1 | 2171/62.7 | 1292/37.3 |